Anzeige
Mehr »
Donnerstag, 18.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853849 | ISIN: JP3463000004 | Ticker-Symbol: TKD
Tradegate
18.09.25 | 15:46
25,870 Euro
-1,00 % -0,260
Branche
Chemie
Aktienmarkt
NIKKEI-225
Singapur
1-Jahres-Chart
TAKEDA PHARMACEUTICAL CO LTD Chart 1 Jahr
5-Tage-Chart
TAKEDA PHARMACEUTICAL CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
25,55025,84017:17
25,73025,87017:14

Aktuelle News zur TAKEDA PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
TAKEDA PHARMACEUTICAL Aktie jetzt für 0€ handeln
04:10Takeda sees China emerging as global innovation hub5
MiTakeda partners with VELA to ship medicines on wind-powered cargo trimaran3
DiTakeda Flat on Hookup with VELA3
DiTakeda to Transport Products Between Europe and the U.S. with Sailing Cargo Vessels4
DiTakeda Pharmaceutical Company Limited: Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran278VELA to operate the world's first sailing cargo trimaran powered by 100 percent wind when at sea1 to sail between Europe and the U.S. Takeda to become the first biopharmaceutical company...
► Artikel lesen
FrTakeda poaches top Lilly exec; Maze soars on early PKU drug data5
11.09.Takeda names Lilly's Rhonda Pacheco as President of the U.S. unit7
11.09.Takeda Appoints Rhonda Pacheco as President of U.S. Business Unit2
10.09.CVS Joins Retailers in Antitrust Battle Over Takeda Drug Deal6
10.09.Takeda faces another 'pay-for-delay' antitrust lawsuit, this one from CVS over heartburn drug Dexilant7
09.09.Research and Markets: Europe Liver Disease Therapeutic Market Analysis Report 2025-2033 Featuring Abbott, Astellas, BMS, Gilead Sciences, GSK, F. Hoffman-La Roche, Merck & Co., Novartis, Sanofi, Pfizer, Takeda - ResearchAndMarkets.com1.103The "Europe Liver Disease Therapeutic Market Forecast 2025" report has been added to ResearchAndMarkets.com's offering. The Europe Liver Disease Therapeutic Market is expected to grow from US$...
► Artikel lesen
09.09.Takeda Is Waking Up the Narcolepsy Market With First-in-Class Drug, But Alkermes Is on Its Heels7
08.09.Takeda, Alkermes lift lid on data for rival narcolepsy hopefuls as race to market heats up10
08.09.Takeda receives FDA approval for Vonvendi sBLA5
08.09.TAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::OREXIN DATA - LANDMARK OVEPOREXTON (TAK-861) PHASE 3 PROGRAM IN NARCOLEPSY TYPE 1 - WORLD SLEEP 20253
08.09.TAKEDA PHARMACEUTICAL CO LTD - 6-K, Report of foreign issuer2
08.09.Takeda's narcolepsy drug shows positive results in phase 3 trials3
08.09.Positive Phase-3-Studiendaten für Takedas Narkolepsie-Wirkstoff24
06.09.FDA Approves Expanded Indication For Takeda's VONVENDI In Von Willebrand Disease1.084TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK, TKPHF, 4502.T) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...
► Artikel lesen
06.09.FDA erweitert Zulassung für Takedas VONVENDI zur Behandlung des von-Willebrand-Syndroms5
Weiter >>
154 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1